Anap­tys­Bio CEO abrupt­ly re­signs less than a week af­ter mid-stage flop

Less than a week af­ter Anap­tys­Bio dropped an­oth­er in­di­ca­tion for its lead drug, the biotech’s long­time CEO has de­cid­ed to tap out.

Hamza Suria ten­dered his res­ig­na­tion on Sun­day, Anap­tys­Bio re­vealed in an SEC fil­ing, giv­ing up the role he’d held for more than 10 years. Daniel Fa­ga, the for­mer COO of Mi­rati Ther­a­peu­tics who joined the biotech’s board of di­rec­tors last De­cem­ber, will serve as CEO in the in­ter­im, Anap­tys­Bio an­nounced Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER